Mometasona furoato Cipla (Mometasone)

Mometasone binds to glucocorticoid receptors in the cells lining the nasal mucosa. The drug‑receptor complex enters the cell nucleus and suppresses the transcription of genes that code for pro‑inflammatory cytokines, chemokines and adhesion molecules, thereby decreasing swelling, mucus production and immune cell infiltration.

The specific dose and frequency are determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms and clinical response. Typical regimens involve one or two sprays per nostril once daily, but the exact regimen should always follow the prescriber’s instructions.

Safety data for mometasone nasal spray in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometasone furoate is a high‑potency intranasal corticosteroid with a low systemic bioavailability, similar to fluticasone propionate. Compared with some older agents, mometasone often requires fewer daily sprays to achieve comparable symptom control, but the choice of product depends on individual response, tolerability and prescriber preference.

The nasal spray should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from moisture, excessive heat and direct sunlight. Keep the device upright and avoid freezing. Do not use the product beyond the expiration date printed on the label.

Before each use, gently shake the bottle, remove the cap and prime the spray if it is the first use. Tilt the head slightly forward, insert the nozzle into one nostril, close the opposite nostril with a finger, and press the actuator to deliver the prescribed number of sprays. Breathe in gently through the nose and repeat in the other nostril if instructed.

Serious but rare adverse events include severe nosebleeds, perforation of the nasal septum and, with prolonged high‑dose use, systemic corticosteroid effects such as adrenal suppression, cataracts or glaucoma. Patients should report any persistent bleeding, visual changes or signs of infection to their healthcare provider promptly.

The spray should be avoided in individuals with known hypersensitivity to mometasone or any component of the formulation, in those with active untreated nasal infections, recent nasal surgery, or severe nasal trauma. Patients on systemic corticosteroids or with uncontrolled systemic fungal infections should also discuss use with a clinician before starting therapy.